Dataset Information

Proteomics of Extracellular Vesicles Produced by Granulicatella adiacens, which causes Infective Endocarditis

ABSTRACT: Granulicatella adiacens is a non-motile, non-spore-forming, facultatively anaerobic Gram-positive coccus. It is part of the normal oral flora but cause serious infections such as infective endocarditis. Many bacterial species produce extracellular vesicles (EVs) as part of normal physiology, but also use it as a virulence strategy. In this study, it was hypothesized that G. adiacens produces EVs that possibly help the species in virulence. Therefore, the objectives were to isolate and characterize EVs produced by these species and to investigate their immune-stimulatory effects. The reference strain G. adiacens CCUG 27809 was cultured on chocolate blood agar for 2 days. From subsequent broth cultures, the EVs were isolated using differential centrifugation and filtration protocol and then observed using scanning electron microscopy. Proteins in the vesicle preparations were identified by nano LC-ESI-MS/MS. The EVs proteomes were analyzed and characterized using different bioinformatics tools. The immune-stimulatory effect of the EVs was studied via ELISA quantification of IL-8, IL-1β and CCL5, major proinflammatory cytokines, produced from stimulated human PBMCs. It was revealed that both G. adiacens and G. elegans produced EVs, ranging in diameter from 30 to 250 nm. Overall, G. adiacens EVs contained 112 proteins. The proteome consist of several ribosomal proteins, DNA associated proteins, binding proteins, and metabolic enzymes. It was also shown that these EVs carry putative virulence factors including moonlighting proteins. These EVs were able to induce the production of IL-8, IL-1β and CCL5 from human PBMCs. The diversity in EVs content indicates that these vesicles may have possible roles in bacterial survival, invasion, host immune modulation as well as infection. Further characterization of the composition and immunogenicity of G. adiacens EVs may provide new insights into virulence mechanisms of this bacterial species.

INSTRUMENT(S): LTQ

ORGANISM(S): Granulicatella Adiacens Atcc 49175

SUBMITTER: Maribasappa Karched

LAB HEAD: Maribasappa Karched

PROVIDER: PXD021414 | Pride | 2020-11-05

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	F009342.csv	Csv
	G.adiacens_EVs.mztab	Mztab
	G.adiacens_EVs_Proteins_Final.xlsx	Xlsx
	G.adiacens_EVs_Proteins_Spectra.pdf	Pdf

Items per page:

1 - 4 of 4

Similar Datasets

Project description:Palmer2014 - Effect of IL-1β-Blocking therapies in T2DM - Disease Condition This is the model with disease state initial conditions. A few changes were made to the model equations in order to bypass the circular dependencies apparent in SBML. Coupled algebraic equations for the species Glucose, Insulin and Proinsulin were changed to reactions which represent the ordinary differential equations found in a previously published model by De Gaetano et al (2008), [MODEL1112110003]. This reference was used by the present authors for the algebraic equations. The original Mathematica code, obtained from the supplementary material of the article can be downloaded from the link below: [Palmer2014_notebook.nb]. This model is described in the article: Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms. Palmér R, Nyman E, Penney M, Marley A, Cedersund G, Agoram B. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 11;3:e118. Abstract: Recent clinical studies suggest sustained treatment effects of interleukin-1β (IL-1β)-blocking therapies in type 2 diabetes mellitus. The underlying mechanisms of these effects, however, remain underexplored. Using a quantitative systems pharmacology modeling approach, we combined ex vivo data of IL-1β effects on β-cell function and turnover with a disease progression model of the long-term interactions between insulin, glucose, and β-cell mass in type 2 diabetes mellitus. We then simulated treatment effects of the IL-1 receptor antagonist anakinra. The result was a substantial and partly sustained symptomatic improvement in β-cell function, and hence also in HbA1C, fasting plasma glucose, and proinsulin-insulin ratio, and a small increase in β-cell mass. We propose that improved β-cell function, rather than mass, is likely to explain the main IL-1β-blocking effects seen in current clinical data, but that improved β-cell mass might result in disease-modifying effects not clearly distinguishable until >1 year after treatment. This model is hosted on BioModels Database and identified by: MODEL1604270002. To cite BioModels Database, please use: BioModels: Content, Features, Functionality and Use. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Project description:Palmer2014 - Effect of IL-1β-Blocking therapies in T2DM - Healthy Condition This is the model with healthy state initial conditions. A few changes were made to the model equations in order to bypass the circular dependencies apparent in SBML. Coupled algebraic equations for the species Glucose, Insulin and Proinsulin were changed to reactions which represent the ordinary differential equations found in a previously published model by De Gaetano et al (2008), [MODEL1112110003]. This reference was used by the present authors for the algebraic equations. The original Mathematica code, obtained from the supplementary material of the article can be downloaded from the link below: [Palmer2014_notebook.nb]. This model is described in the article: Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms. Palmér R, Nyman E, Penney M, Marley A, Cedersund G, Agoram B. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 11;3:e118. Abstract: Recent clinical studies suggest sustained treatment effects of interleukin-1β (IL-1β)-blocking therapies in type 2 diabetes mellitus. The underlying mechanisms of these effects, however, remain underexplored. Using a quantitative systems pharmacology modeling approach, we combined ex vivo data of IL-1β effects on β-cell function and turnover with a disease progression model of the long-term interactions between insulin, glucose, and β-cell mass in type 2 diabetes mellitus. We then simulated treatment effects of the IL-1 receptor antagonist anakinra. The result was a substantial and partly sustained symptomatic improvement in β-cell function, and hence also in HbA1C, fasting plasma glucose, and proinsulin-insulin ratio, and a small increase in β-cell mass. We propose that improved β-cell function, rather than mass, is likely to explain the main IL-1β-blocking effects seen in current clinical data, but that improved β-cell mass might result in disease-modifying effects not clearly distinguishable until >1 year after treatment. This model is hosted on BioModels Database and identified by: MODEL1604270002. To cite BioModels Database, please use: BioModels: Content, Features, Functionality and Use. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Dataset Information

Proteomics of Extracellular Vesicles Produced by Granulicatella adiacens, which causes Infective Endocarditis

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets